Navigation Links
Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need
Date:9/27/2010

NEW YORK, Sept. 27 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today provided an update to its development pipeline, which includes 118 programs from Phase 1 through registration.  The updated pipeline continues to reflect Pfizer's ongoing investment in high-priority disease areas with considerable unmet medical need.  

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

"We continue to be confident in the progression of our late-stage pipeline and have advanced three compounds into registration since our last portfolio update," said Ian Read, president of Pfizer's Worldwide Biopharmaceutical Businesses.  "We have a strong pipeline with programs in development across important therapeutic areas including oncology, neuroscience and inflammation.  We remain committed to growing our biologics and vaccines development programs."

"Building on the rapid integration of Pfizer and Wyeth, the new Pfizer brings a wealth of scientific approaches and technologies to our key investment areas, and we are developing novel product candidates across all phases of development," said Mikael Dolsten, MD, PhD, president of Pfizer's Worldwide Research and Development.  "We are leveraging the best product assets of our legacy organizations and driving important steps forward in strategy and method to deliver a portfolio of next generation medicines and vaccines."

Pfizer now has 118 programs in Phase 1 through registration, compared to 133 programs at its last pipeline update in January, 2010.  This reflects 25 programs that are new or have advanced along the pipeline and 31 programs that have been discontinued since the last update.  The current pipeline includes 26 programs in Phase 3 and nine programs in registration, as well as 27 biologics and four vaccines across all phases of development.

Detailed information about Pfizer's pipeline is available at www.pfizer.com/pipeline.  Such information includes an overview of the company's research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs, mechanism of action.  

DISCLOSURE NOTICE: The information contained in this release is as of September 27, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about the Company's development pipeline that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications and supplemental drug applications that have been or may be filed for products in development and additional indications for certain in-line products, as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products and such additional indications; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and 8-K.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Corporate Presentation Updated
2. Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology
3. RF Technologies(R) Installs Updated Version of its Safe Place(R) Solution for Infant Security at Sutter Tracy Community Hospital
4. Advanced Life Sciences Submits Updated Special Protocol Assessment to FDA for Restanza in Community Acquired Bacterial Pneumonia
5. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
6. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
8. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
9. Newly Updated Pharmacy State Law Compendium Available
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):